Biomarkers Matter in Early Phase Clinical Trials: How Assay Design Impacts Drug Development

Biomarkers are transforming early phase clinical trials, offering significant value when supported by fit-for-purpose assay design.

Early phase clinical trials set the trajectory of a drug, and biomarkers are increasingly central to that trajectory. Across therapeutic areas, biomarkers inform dose selection, characterize pharmacodynamic response and provide early signals of efficacy. Clinical development teams are often under pressure to generate decision-ready data earlier, and biomarkers offer a path to more informed and capital-efficient progression. Their value, however, is not inherent. It depends on how they are designed, measured and interpreted.

Rethink Biomarkers as Decision Tools for Early Phase Development

The role of biomarkers in early phase has evolved from minor exploratory endpoints to decision-enabling tools. When implemented effectively, they can:

• Provide mechanistic evidence of target engagement
• Inform dose and schedule optimization
• Enable earlier go/no-go decisions
• Support patient stratification strategies

However, unlike pharmacokinetics or immunogenicity, biomarkers do not operate within a standardized regulatory or methodological framework. Their diversity across assay platforms, biological matrices and clinical contexts introduces variability that must be actively managed.

As a result, the question for drug developers is now centered around what the data’s context of use will be and whether the data generated will be fit for purpose.

Why Assay Design Is the Critical Control Point in Early Phase Trials

A biomarker is only as useful as the assay employed to measure it, explains Matthew Lawless, PhD, Associate Director of Bioanalysis at Syneos Health. In a recent publication of Bioanalysis, Dr. Lawless et al. described the development and qualification of an electrochemiluminescence (ECL) assay for detecting urinary neurotrophin receptor p75 (p75NTR), a biomarker associated with neurodegenerative disease progression specifically in patients with ALS. The highlight of this analyte is that it is collected in urine and does not require a blood draw or spinal tap for measurement.

The assay demonstrated high sensitivity, accuracy and reproducibility across a wide dynamic range and displayed the ability to detect endogenous analyte in >98% of samples. Importantly, it was designed using commercially available reagents and widely accessible instrumentation, enabling scalability across clinical settings, according to the researchers.

Drug development teams need to see biomarkers as prerequisites for generating clinical trial strategies. Without that foundation, biomarker data risks remaining descriptive rather than decision-driving.

From Analytical Performance to Clinical Utility

For early phase leaders, the distinction between measurement and meaning is critical. Analytical performance alone does not guarantee clinical utility. What matters is whether the assay can reliably quantify endogenous biomarker levels within the biological context of interest.

Operationalizing Biomarkers in Early Phase Development

The integration of biomarkers into early phase is an operational challenge. Too often, biomarker strategies are considered or introduced late in study design and/or treated as exploratory add-ons. In these cases, misalignment between assay capability, sampling strategy and clinical endpoints can limit their impact.

Leading development teams are taking a more integrated approach:

• Embedding biomarker strategy within protocol design
• Aligning assay performance characteristics with decision points
• Ensuring coordination across clinical pharmacology, bioanalysis and operations
• Selecting technologies that balance sensitivity, robustness and scalability

This shift reflects a broader change in how early phase is approached, shifting from a sequence of activities to a decision-oriented system.

The Future: Biomarkers as Drivers of Precision Development

Advances in assay technologies are accelerating the role of biomarkers in drug development. Electrochemiluminescence platforms, along with emerging technologies such as multiplex assays and ultra-sensitive detection systems such as proximity ligation assays, are enabling:

• More precise pharmacodynamic endpoints
• Earlier detection of biological response
• Greater integration with companion diagnostics
• Improved scalability across global trials

Simultaneously, regulatory expectations are evolving, placing greater emphasis on assay robustness, reproducibility and clinical relevance. Looking ahead, the convergence of biomarker science, automation and AI-driven analytics will further shift early phase development toward precision-led decision-making.

A Strategic Imperative for Development Leaders

For leaders overseeing early phase programs, the implication is clear: Biomarkers are a determinant of their success.

The critical questions are no longer about inclusion, but about execution:

• Are biomarker strategies aligned with key development decisions?
• Are assays designed to generate reliable, interpretable data?
• Is cross-functional alignment in place to operationalize biomarker insights?

In an environment where early phase defines downstream success, the ability to translate biomarker science into decision-ready data is becoming a core competitive advantage.

Contributors